Estamos aún en medio de la pandemia y seguimos teniendo muchas preguntas acerca del origen y la propagación del nuevo coronavirus, así como de sus letales consecuencias por todo el mundo. En los centros de investigación más importantes se han ensayado algunas respuestas sobre su origen y performance, pero en ningún caso se han obtenido respuestas definitivas. Esta situación de incertidumbre propicia activos caldos de cultivo para numerosas y disímiles interpretaciones, y muchas de ellas son encendidas por las llamadas teorías de la conspiración. Si hay, pues, en este largo y lamentable proceso de contagio histórico para la humanidad, una gran víctima general, ella es la información sustentada, es decir, elaborada con rigor y responsabilidad. Sobre todo en los llamados medios sociales de internet.
BackgroundAllergen-specific immunotherapy consists of administering gradually increasing doses of the allergen, to which the patient is sensitized, aiming at achieving tolerance to it and decreasing clinical symptoms. The sublingual immunotherapy (SLIT) was introduced as an alternative to subcutaneous route. Its use is being increased in the world and in Cuba, using standardized vaccines owing to greater safety. The objective of this study was to determine the safety of sublingual standardized vaccines of 3 domestic mite species (Valergen, Cuba) and its adverse events in allergic patients from the Calixto García University Hospital in Havana, as well as the frequency of its prescription.MethodsDescriptive and cross sectional study design, which included 130 patients with treatment of SLIT with VALERGEN-DP (Dermatophagoides pteronyssinus), VALERGEN-DS (D. siboney) and VALERGEN-BT (Blomia tropicalis) (BIOCEN, Cuba), who attended the Allergy Service in the period January-September 2010. Age distribution: mean 19.6 years (range 1–75), 40.7 % was younger than 18 years.ResultsThe multiallergen vaccine was the type of vaccine most used (63.8%). The most common allergen was D. pteronyssinus followed by B. tropicalis. 71.55% of administered allergens vaccines were in maintenance phase. We found 4 adverse events (3.1% of patients), all local, mild, and not requiring treatment or change of vaccination dosing schedule.ConclusionsThe Valergen vaccines by sublingual route are safe and well tolerated in Cuban allergic patients.
BackgroundThe specific active immunotherapy, employing vaccine of allergen of mite is a treatment considered as effective for the respiratory allergy and asthma. The sublingual route has minor risk of systematises reactions. The objective of this study was to determine the therapeutic effect and security of sublingual immunotherapy (ITSL) employing the standard vaccine VALERGEN-DP (BIOCEN, CUBA) in a population of asthmatic Cuban patients.MethodsA phase II Clinical Trials double blind, placebo controlled in a total of 40 adult patients with mild or moderate asthma and specific sensibility preponderant to this mite. Half of patients received drops by sublingual route with growing doses up to 2000 UB.ResultsThe treatment was effective in the reduction of clinical symptoms and medication intake as compared to conventional treatment in control group. The cutaneous sensibility to this mite was significant reduced, increasing in 1.9 log; the amount of necessary allergen to provoke a positive Prick Test. An improvement of the lung function was observed with a significant reduction (P < 0.05) of expiratory pick flow variability. The frequency of local reactions were only 0.58% of administration.ConclusionsThe VALERGEN-DP vaccine is an effective treatment and profitable against asthma in our population and guarantee its generalization in the Allergy Services of our health system.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.